

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <b>Barth Jay</b>			2. Issuer Name and Ticker or Trading Symbol <b>AMICUS THERAPEUTICS, INC. [ FOLD ]</b>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) <input checked="" type="checkbox"/> <b>Chief Medical Officer</b> Other (specify below) _____			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <b>07/07/2020</b>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person _____			
C/O AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE			4. If Amendment, Date of Original Filed (Month/Day/Year)						
(Street)	(City)	(State)	(Zip)						
<b>CRANBURY</b>	<b>NJ</b>	<b>08512</b>							

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/07/2020		M		51,531	A	\$8.61	214,735	D	
Common Stock	07/07/2020		M		64,601	A	\$9.03	279,336	D	
Common Stock	07/07/2020		M		12,804	A	\$10.04	292,140	D	
Common Stock	07/07/2020		M		50,052	A	\$12.28	342,192	D	
Common Stock	07/07/2020		s <sup>(1)</sup>		178,988	D	\$15.9002 <sup>(2)</sup>	163,204	D	
Common Stock	07/08/2020		M		16,910	A	\$8.61	180,114	D	
Common Stock	07/08/2020		M		16,549	A	\$9.03	196,663	D	
Common Stock	07/08/2020		M		8,599	A	\$10.04	205,262	D	
Common Stock	07/08/2020		M		22,052	A	\$12.28	227,314	D	
Common Stock	07/08/2020		s <sup>(1)</sup>		64,110	D	\$15.9191 <sup>(3)</sup>	163,204	D	
Common Stock								20	I	By Daughter

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Options (right to buy)	\$8.61	07/07/2020		M			51,531	(4)	01/02/2025	Common Stock	51,531	\$0.00	28,469	D	
Stock Options (right to buy)	\$9.03	07/07/2020		M			64,601	(4)	01/04/2026	Common Stock	64,601	\$0.00	25,399	D	
Stock Options (right to buy)	\$10.04	07/07/2020		M			12,804	(5)	01/02/2029	Common Stock	12,804	\$0.00	69,840	D	
Stock Options (right to buy)	\$12.28	07/07/2020		M			50,052	(4)	06/01/2025	Common Stock	50,052	\$0.00	39,948	D	
Stock Options (right to buy)	\$8.61	07/08/2020		M			16,910	(4)	01/02/2025	Common Stock	16,910	\$0.00	11,559	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (right to buy)	\$9.03	07/08/2020		M			16,549	(4)	01/04/2026	Common Stock	16,549	\$0.00	8,850	D	
Stock Options (right to buy)	\$10.04	07/08/2020		M			8,599	(6)	01/02/2029	Common Stock	8,599	\$0.00	61,241	D	
Stock Options (right to buy)	\$12.28	07/08/2020		M			22,052	(4)	06/01/2025	Common Stock	22,052	\$0.00	17,896	D	

**Explanation of Responses:**

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from \$15.90 to \$15.91. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from \$15.90 to \$16.12 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- All of the options were fully vested and exercisable as of the transaction date.
- As of July 7, 2020, 30,987 options were fully vested and exercisable and 51,657 remained unvested from this grant.
- As of July 8, 2020, 18,183 options were fully vested and exercisable and 51,657 remained unvested from this grant.

**Remarks:**

/s/ Christian Formica, Attorney-in-Fact 07/09/2020

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**